Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients: A Systematic Review and Meta-Analysis

Rahajeng N Tunjungputri, Erpryta N Tetrasiwi, Nadia A Mulansari, Kuntjoro Harimurti, Erni J Nelwan


Background: The use of anticoagulants has been endorsed by different hematological societies as coagulation abnormalities are key features of COVID-19 patients. This systematic review and meta-analysis aims to provide the most recent update on available evidence on the clinical benefits and risk of oral and parenteral anticoagulants, as well agents with anticoagulant properties, in hospitalized and post-discharge COVID-19 patients.
Methods: This systematic review synthesizes data on the outcome of anticoagulation in hospitalized and post-discharge COVID-19 patients. Dichotomous variables from individual studies were pooled by risk ratio (RR) and their 95% confidence interval (95% CI) using the random-effects model. Meta-analyses were performed when feasible. Results: We included 32 studies from 2.815 unique citations, including 7 randomized clinical trials. A total of 33.494 patients were included. Outcomes measured include mortality and survival rates, the requirement for ICU care and mechanical ventilation. A pooled meta-analysis favors anticoagulant compared to no anticoagulant with reduced mortality in hospitalized patients (RR 0,55; 95%CI 0,43-0,66; p<0,001). Higher dose of anticoagulant also showed treatment benefit compared to standard prophylactic dose in selected populations (RR 0,68; 95%CI 0,40-0,96; p<0,001). Regular, pre-hospital anticoagulation prior to hospitalization yielded mixed result. There are currently no data on the benefit of anticoagulation on post-discharge COVID-19 patients. Conclusion: Determination of the presence of thrombosis in COVID-19 is important, as therapeutic dosage of anticoagulants, rather than prophylatic dose, would be indicated in such clinical situation. Anticoagulants were found to decrease the mortality of hospitalized COVID-19. The results from this study are important in the tailored treatment of COVID-19 patients. Further studies on the need for oral anticoagulation for outpatients or post-discharge is warranted. This study has been registered in PROSPERO database (CRD42020201418).


COVID-19; anticoagulant; VTE; thromboprophylaxis


World Health Organization. HO Coronavirus Disease (COVID-19) Dashboard 2020 [Available from:

Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020.

Gómez-Mesa JE, Galindo-Coral S, Montes MC, Martin AJMJC. Thrombosis and coagulopathy in COVID-19. 2020:100742.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine. 2020:1-10.

Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thrombosis Research. 2020.

Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thrombosis Haemostasis. 2020.

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thrombosis Haemostasis. 2020.

Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: Awareness of an increased prevalence. Circulation. 2020.

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. 2020.

Thachil J, Tang N, Gando S. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. 2020;18(5):1023-6.

Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment. J Thrombosis Haemostasis. 2020.

Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and standardization committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. 2020;18(8):1859-65.

Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. 2021;5(3):872-88.

Spyropoulos AC, Ageno W, Barnathan ES. Hospital-based use of thromboprophylaxis in patients with COVID-19. Lancet. 2020;395(10234):e75.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. J Thrombosis Thrombolysis. 2020;181(2):271-80.e8.

Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12(6):629.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med. 2009;6(7):e1000097.

Lo CK-L, Mertz D, Loeb MJBmrm. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. 2014;14(1):1-5.

Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. 2019;366.

Higgins JP, Thompson SGJS. Quantifying heterogeneity in a meta‐analysis. 2002;21(11):1539-58.

Macaskill P, Walter SD, Irwig LJSim. A comparison of methods to detect publication bias in meta‐analysis. 2001;20(4):641-54.

Suurmond R, van Rhee H, Hak TJR. Introduction, comparison, and validation of Meta‐Essentials: a free and simple tool for meta‐analysis. 2017;8(4):537-53.

Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Internal Medicine. 2021.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thrombosis Haemostasis. 2020;18(5):1094-9.

Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. 2020:1-4.

Musoke N, Lo KB, Albano J, et al. Anticoagulation and bleeding risk in patients with COVID-19. Thrombosis Research. 2020;196:227-30.

ATTACC A-a, Investigators R-C. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. New England J Med. 2021;385(9):790-802.

REMAP-CAP A-a, Investigators A. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. New Engl J Med. 2021;385(9):777-89.

Di Castelnuovo A, Costanzo S, Antinori A, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: The Multicenter Italian CORIST Study. 2021.

Lemos ACB, do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). 2020;196:359-66.

Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. 2021;372.

Lopes RD, Furtado RH, Macedo AVS, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. 2021.

Hsu A, Liu Y, Zayac AS, Olszewski AJ, Reagan JLJTr. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. 2020;196:375-8.

Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. 2020;76(16):1815-26.

Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020.

Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020.

Mouhat B, Besutti M, Bouiller K, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. European Respiratory Journal. 2020;56(4).

Ionescu F, Grasso-Knight G, Castillo E, et al. Therapeutic anticoagulation delays death in COVID-19 patients: cross-sectional analysis of a prospective cohort. TH open: Companion Journal to Thrombosis and Haemostasis. 2020;4(3):e263.

Ionescu F, Jaiyesimi I, Petrescu I, et al. Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis. Eur J Haematol. 2020.

Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. Journal of Thrombosis and Thrombolysis. 2020:1-4.

Tomasoni D, Inciardi RM, Lombardi CM, et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study. European Journal of Heart Failure. 2020.

Yu Y, Tu J, Lei B, et al. Incidence and risk factors of deep vein thrombosis in hospitalized COVID-19 patients. Clinical and Applied Thrombosis/Hemostasis. 2020;26:1076029620953217.

Boari GEM, Chiarini G, Bonetti S, et al. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. Bioscience Reports. 2020;40(12).

Perepu U, Chambers I, Wahab A, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomised controlled trial. 2021.

Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. 2021;325(16):1620-30.

Yethindra V, Tagaev T. Decreased mortality among hospitalized coronavirus disease 2019 patients who underwent anticoagulant therapy with heparin. Indian Journal of Pharmacology. 2020;52(4):337.

Khider L, Gendron N, Goudot G, et al. Curative anticoagulation prevents endothelial lesion in COVID‐19 patients. Journal of Thrombosis and Haemostasis. 2020;18(9):2391-9.

Rivera‐Caravaca JM, Núñez‐Gil IJ, Vivas D, et al. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID‐19. European Journal of Clinical Investigation. 2020; 51(1):e13436.

Rossi R, Coppi F, Talarico M, Boriani G. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. European Journal of Internal Medicine. 2020.

Russo V, Di Maio M, Attena E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacological Research. 2020:104965.

Ménager P, Brière O, Gautier J, et al. Regular use of vka prior to covid-19 associated with lower 7-day survival in hospitalized frail elderly covid-19 patients: The geria-covid cohort study. 2021;13(1):39.

Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with COVID-19: a case series. Critical Care. 2020;24(1):1-4.

Jang S, Rhee J-Y. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. International Journal of Infectious Diseases. 2020.

Rambaldi A, Gritti G, Micò MC, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225(6):152001.

Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Critical Care. 2015;19(1):287.

Porfidia A, Pola R. Correction to: Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines. 2020:1.

Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708-20.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

Gralinski LE, Bankhead A, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio. 2013;4(4):e00271-13.

Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatric Nephrology. 2018;33(8):1297-307.

Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132(2):141-7.

Malato A, Dentali F, Siragusa S, et al. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfusion. 2015;13(4):559.

Chowdhury JF, Moores LK, Connors JMJNEJoM. Anticoagulation in hospitalized patients with COVID-19. 2020;383(17):1675-8.

Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID‐2019. Research and Practice in Thrombosis and Haemostasis. 2020.

Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. The Lancet Haematology. 2020;7(5):e362-e3.

Porfidia A, Pola R. Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines. 2020:1-4.

Baumann Kreuziger L LA, Garcia D, Cuker A, Cushman M, Connors JM. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions 2020 [Available from:

Tremblay D, van Gerwen M, Alsen M, et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. 2020;136(1):144-7.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.